CG
EBS icon

Clinton Group’s Emergent Biosolutions EBS Stock Holding History

Clinton Group’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-16,593
Closed -$482K – 643
2017
Q1 		$482K Sell
16,593
-592
-3% -$18K 0.03% 639
2016
Q4 		$564K Sell
17,185
-14,856
-46% -$445K 0.03% 539
2016
Q3 		$1.01M Buy
32,041
+4,927
+18% +$143K 0.05% 476
2016
Q2 		$762K Buy
+27,114
New +$1.06M 0.03% 555

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Clinton Group's EBS Position: Q2 2017 in Review

Clinton Group sold out of Emergent Biosolutions (EBS) in Q2 2017, closing a stake of 16,593 shares — an estimated $482K sold.

Clinton Group first reported a position in EBS in Q2 2016 and held it in 4 quarters. The position peaked at $1.01M in Q3 2016. 181 funds tracked by Wall St. Rank hold EBS as of Q2 2017.

  • Clinton Group reported no remaining Emergent Biosolutions position as of Q2 2017 after selling out during the quarter.
  • Clinton Group sold 16,593 Emergent Biosolutions shares in Q2 2017, an estimated $482K.
  • Clinton Group first reported a position in Emergent Biosolutions in Q2 2016 and held it in 4 quarters.
  • Clinton Group's Emergent Biosolutions position peaked at $1.01M in Q3 2016.
  • 181 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2017.

Based on Clinton Group's 13F filing for Q2 2017, filed 14 Aug 2017.